AR091724A1 - Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica - Google Patents

Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica

Info

Publication number
AR091724A1
AR091724A1 ARP130102454A AR091724A1 AR 091724 A1 AR091724 A1 AR 091724A1 AR P130102454 A ARP130102454 A AR P130102454A AR 091724 A1 AR091724 A1 AR 091724A1
Authority
AR
Argentina
Prior art keywords
fampridine
laquinimod
multiple sclerosis
treatment
combination
Prior art date
Application number
Other languages
English (en)
Inventor
Kaye Joel
Tarcic Nora
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of AR091724A1 publication Critical patent/AR091724A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Método de tratamiento de un sujeto que sufre de esclerosis múltiple o que presenta un síndrome clínicamente aislado que comprende administrar al sujeto fampridina como una terapia adyuvante o en combinación con laquinimod. Un envase que comprende laquinimod y fampridina para tratar a un sujeto afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado. Fampridina para su uso como una terapia adyuvante o en combinación con laquinimod en el tratamiento de un sujeto que sufre de esclerosis múltiple o que presenta un síndrome clínicamente aislado. Composición farmacéutica que comprende laquinimod y fampridina para su uso en el tratamiento de un sujeto afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado. Uso de laquinimod y fampridina en la preparación de una combinación para tratar a un sujeto que sufre de esclerosis múltiple o que presenta un síndrome clínicamente aislado. Reivindicación 59: La composición farmacéutica de cualquiera de las reivindicaciones 54 - 57, caracterizada porque la cantidad de laquinimod en la composición es de 0,25 - 2,0 mg. Reivindicación 68: La composición farmacéutica de cualquiera de las reivindicaciones 54 - 66, caracterizada porque la cantidad de fampridina en la composición es de 1,0 - 20 mg.
ARP130102454 2012-07-12 2013-07-10 Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica AR091724A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261670758P 2012-07-12 2012-07-12

Publications (1)

Publication Number Publication Date
AR091724A1 true AR091724A1 (es) 2015-02-25

Family

ID=49914160

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102454 AR091724A1 (es) 2012-07-12 2013-07-10 Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica

Country Status (16)

Country Link
US (2) US20140017226A1 (es)
EP (1) EP2872217A4 (es)
JP (1) JP2015522077A (es)
KR (1) KR20150038072A (es)
CN (1) CN104582793A (es)
AR (1) AR091724A1 (es)
AU (1) AU2013290181A1 (es)
BR (1) BR112015000616A2 (es)
CA (1) CA2873229A1 (es)
EA (1) EA201590191A1 (es)
HK (1) HK1209672A1 (es)
IL (1) IL236230A0 (es)
MX (1) MX2015000485A (es)
TW (1) TW201408300A (es)
UY (1) UY34896A (es)
WO (1) WO2014011827A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014018485A8 (pt) 2012-02-03 2017-07-11 Teva Pharma Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf
MX2014009889A (es) 2012-02-16 2014-11-13 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos.
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
AU2013341506A1 (en) 2012-11-07 2015-06-04 Teva Pharmaceutical Industries Ltd. Amine salts of Laquinimod
SG11201506409RA (en) 2013-03-14 2015-09-29 Teva Pharma Crystals of laquinimod sodium and improved process for the manufacture thereof
CN106573014A (zh) * 2014-04-29 2017-04-19 梯瓦制药工业有限公司 用于治疗具有高残疾状况的复发‑缓解型多发性硬化症(rrms)的患者的拉喹莫德
GB2540163A (en) * 2015-07-07 2017-01-11 Univ London Queen Mary Combination therapy for treating multiple sclerosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726339D0 (en) * 1997-12-13 1998-02-11 Zeneca Ltd Human-derived tissue-specific potassium channel
US20090082471A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
ES2329327B1 (es) * 2008-03-19 2010-09-17 Proyecto De Biomedicina Cima, S.L. Combinaciones sinergicas de 5'-metiltioadenosina.
TW201010703A (en) * 2008-09-10 2010-03-16 Acorda Therapeutics Inc Methods of using sustained release aminopyridine compositions
RS54328B1 (en) * 2009-06-19 2016-02-29 Teva Pharmaceutical Industries Ltd. MULTIPLE TREATMENT OF LAKVINIMOD SCLEROSIS
WO2013055907A1 (en) * 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod

Also Published As

Publication number Publication date
EP2872217A1 (en) 2015-05-20
CN104582793A (zh) 2015-04-29
US20160235735A1 (en) 2016-08-18
UY34896A (es) 2014-02-28
US20140017226A1 (en) 2014-01-16
KR20150038072A (ko) 2015-04-08
CA2873229A1 (en) 2014-01-16
MX2015000485A (es) 2015-04-08
AU2013290181A1 (en) 2015-02-26
WO2014011827A1 (en) 2014-01-16
TW201408300A (zh) 2014-03-01
HK1209672A1 (en) 2016-04-08
EA201590191A1 (ru) 2015-06-30
IL236230A0 (en) 2015-01-29
EP2872217A4 (en) 2016-03-16
BR112015000616A2 (pt) 2017-06-27
JP2015522077A (ja) 2015-08-03

Similar Documents

Publication Publication Date Title
AR090491A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
AR091724A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
BR112014008731A2 (pt) tratamento de esclerose múltipla com combinação de laquinimode e fingolimode
MX2014001050A (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero.
WO2015054619A8 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
EA201692506A3 (ru) Ингибиторы репликации вирусов гриппа
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
RU2018145985A (ru) Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
BR112015001847A8 (pt) Composições e tratamento para doenças e distúrbios nos olhos
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
WO2015123423A3 (en) Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
EA201490254A1 (ru) Комбинированное лечение гепатита с
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
EA201591507A1 (ru) Лечение рассеянного склероза лахинимодом
EA201270747A1 (ru) Композиции и способы для профилактики и лечения ран
BR102012028120B8 (pt) Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento
EA201071350A1 (ru) Композиции и способы для лечения воспаления роговицы
BR112015007095A8 (pt) derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados, composição farmacêutica compreendendoos e uso dos referidos derivados
WO2013038200A3 (en) Neurodevelopmental disorders

Legal Events

Date Code Title Description
FB Suspension of granting procedure